NEW YORK, NY / ACCESSWIRE / June 23, 2017 / It was a disappointing day for Teva Pharmaceutical Industries on Thursday, but judging by the gains the stock saw yesterday nobody would have known it. The pharmaceutical company has been ordered by a Delaware judge to pay up to GlaxoSmithKline for willfully infringing on a patent covering of the company's drug Coreg. Geron Corporation also saw shares climb higher, without any major catalyst to explain the move aside from it being revealed that the average price target of the stock from analysts is $3.50.

RDI Initiates Coverage on:

Geron Corporation
https://ub.rdinvesting.com/news/?ticker=GERN

Teva Pharmaceutical Industries Limited
https://ub.rdinvesting.com/news/?ticker=TEVA

Geron Corporation's shares closed up 2.80% on Thursday with a little over 1.3 million shares traded. There was no significant news for the biotech company yesterday but it was revealed that analysts have set a price target of $3.50 on the stock. According to MarketBeats.com, six research firms have a consensus rating of "Buy" on Geron shares. While three have a "hold" rating on the stock, the other three have a "buy" rating. The analysts who have covered the stock over the past year have an average 1-year target price of 3.50 on it. Shares of Geron closed at $2.94 on Thursday. The company is developing anti-cancer therapies based on telomerase inhibitors.

Access RDI's Geron Corporation Research Report at:
https://ub.rdinvesting.com/news/?ticker=GERN

Teva Pharmaceutical Industries Limited's shares closed up 4.73% on Thursday. The gains came surprisingly after a U.S. jury ordered the company to pay GlaxoSmithKline Plc more than $235 million. The jury has ruled that Teva willfully had infringed a patent covering GSK's blood pressure drug Coreg. Perhaps investors were encouraged that Teva may plan to appeal. The company said in a statement, "We still intend to present our equitable defenses to the court at a separate hearing which could eliminate the liability determination or significantly reduce the assessed damages. We are also considering an appeal." In more positive news, last week analyst Irina Koffler of Mizuho upped her price target on the stock from $25 to $30 and upgraded Teva from "underperform" to "neutral."

Access RDI's Teva Pharmaceutical Industries Research Report at:
https://ub.rdinvesting.com/news/?ticker=TEVA

Our Actionable Research on Geron Corporation (NASDAQ: GERN) and Teva Pharmaceutical Industries Limited (NYSE: TEVA) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com